About The Study:
RSV is a very common, highly contagious virus that causes infection of the respiratory tract in people of all ages. In the Rochester climate, symptoms usually develop during fall and winter. In many people, the disease is quite mild and can produce cold-like symptoms. However, in older adults, and people with chronic diseases such as chronic lung or cardiac disease or diabetes, it can be very serious and result in hospitalization or death. There is currently no vaccine available to the general public to prevent this infection and antibiotics are not helpful as this infection is viral.
The purpose of the research study is to evaluate the safety and immune response of the investigational vaccine given to prevent respiratory syncytial virus (RSV) in older adults. The research study will last approximately 12 months with 4 visits to our office. In the 50-59 age group, there is a 33% chance of a placebo for this study. If you are 60 years or above, all participants will receive the study vaccine.
There is no cost for participating in the research study and you may be compensated per visit for your time and travel if you qualify.
- 50+ years of age
- Generally healthy; those with stable lung, heart, kidney, and liver disease and diabetes may still be eligible
- *Please note, that other conditions may apply